

Transform LDL-C management Choose **LEQVIO**[®] for early, strong and LDL-C goal attainment^{*1-6}

LEQVIO[®] uniquely lowers LDL-C[†] with two injections a year (after 2 initial doses),[‡] helping your eligible patients reach their LDL-C goal early and maintain it over the long-term.^{§1-6}

^{*} In clinical trials, LEQVIO[®] allowed 75% patients (N=170) to achieve their LDL-C goals by Day 60* and provided 52% LDL-C reduction at Month 17 (mean difference vs placebo from baseline [N=1,561; 95% CI: -55, -49; p<0.0001]) on top of statins¹⁻³ in line with the ESC 2019 guidelines (minimum 50% reduction after an event). LDL-C reduction was maintained during each 6-month dosing interval.¹⁻³

[†] From baseline.

[‡] LEQVIO[®] is administered as single subcutaneous injections at the start of treatment, again at 3 months and every 6 months thereafter.¹

[§] The main adverse events observed with LEQVIO[®] in clinical trials were mostly mild injection-site reactions (8.2% with LEQVIO[®] vs 1.8% with placebo).¹

LEQVIO[®] (inclisiran) is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:¹
• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
• alone or in combination with other lipid lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

CI, confidence interval; **ESC**, European Society of Cardiology; **LDL-C**, low-density lipoprotein cholesterol

References: 1. LEQVIO[®] Core Data Sheet. Novartis Pharma AG; 2023. 2. Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. *Cardiovasc Res.* 2024;120(12):1400-1410. doi:10.1093/cvr/cvae109. 3. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med.* 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387. 4. Hu Y, Lesogor A, Lee CW, et al. Efficacy and safety of inclisiran in Asian patients: results from ORION-18. *JACC Asia.* 2023;4(2):123-134. doi:10.1016/j.jacasi.2023.09.006. 5. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med.* 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758. 6. Knowlton KU, Nayar AM, Anderson JL, et al. LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION. Presentation at: National Lipid Association's 2025 Annual Scientific Sessions; May 29-June 1, 2025; Miami, FL. 7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in *Eur Heart J.* 2020;41(44):4255. doi:10.1093/eurheartj/ehz826]. *Eur Heart J.* 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

August/2026/FUSE ID 11771904

 **NOVARTIS** Reimagining medicine, together.

Novartis Kuwait for Promotion of Products
SPC Terrace Mall,
Floor 2 Office 5& 6, Salem Al Mubarak Street 26
Ln, Salmiya, Kuwait.
Phone: +96522059200
www.novartis.com

Scan for NSS

